Women with recurrent or persistent ovarian cancer wanted for research study


A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Obstetrics & Gynecology

Duska Linda, R

UVa Health System, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology seeks Women, 18 and older with recurrent or persistent ovarian cancer for research study. The purpose of the study is to test the efficacy and safety of a novel agent, pazopanib, as an adjunct to a standard treatment, gemcitabine, for recurrent or persistent ovarian cancer. Study involves routine history and physical exam, tumor evaluations with CT scans, and routine blood tests. Participation in this study will continue until disease progression and/or inability to tolerate treatment. ? Experimental medication will be provided free of charge. ? No compensation is provided for this study. Contact Information: For more information please contact: • Sanja Arapovic • 434-924-2745 / su2x@virginia.edu • IRB-HSR # 16153 Principal Investigator: Linda Duska, MD

Ovarian Cancer

Cancer (Oncology)


No Compensation

Sanja Arapovic